(Q27489398)

6

object named as

Adrian M Di Bisceglie

0 references

Elizabeth M. Brunt

3

object named as

Elizabeth M Brunt

0 references

author name string

Sarah L George

1

0 references

Bruce R Bacon

2

0 references

Kusal L Mihindukulasuriya

4

0 references

Joyce Hoffmann

Performance Evaluation of the VERSANT HCV RNA Qualitative Assay by Using Transcription-Mediated Amplification

5

0 references

language of work or name

English

0 references

publication date

March 2009

0 references

published in

Hepatology

0 references

volume

49

0 references

issue

3

0 references

page(s)

729-38

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731713

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731713

Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731713

Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731713

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731713

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731713

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

2 June 2018

1 reference

Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon

21 January 2018

1 reference

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

21 January 2018

1 reference

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C.

21 January 2018

1 reference

Time course of histological changes in patients with a sustained biochemical and virological response to interferon-alpha therapy for chronic hepatitis C virus infection

21 January 2018

1 reference

Long-term course of interferon-treated chronic hepatitis C.

21 January 2018

1 reference

Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications

21 January 2018

1 reference

A comparison between the phenol-chloroform method of RNA extraction and the QIAamp viral RNA kit in the extraction of hepatitis C and GB virus-C/hepatitis G viral RNA from serum

21 January 2018

1 reference

Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon.

21 January 2018

1 reference

Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival

21 January 2018

1 reference

Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study

21 January 2018

1 reference

Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon

21 January 2018

1 reference

Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731713

Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy

27 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19072828

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/HEP.22694

1 reference

1 reference

1 reference

PubMed publication ID

19072828

1 reference